Donna Ambrosino, MD

WHO, CEPI, ClearSite Antibodies

Dr. Ambrosino has had a career for over 30 years as a scientific leader for biologics and vaccine development. Most recently she served as an independent consultant to CEPI regarding development of COVID-19 vaccines having previously advised WHO during the SARS 2003 epidemic and on-site assessment of vaccine companies in China. She has recently co-founded ClearSite Antibodies LLC. Until November 2019, she was CEO of Nosocomial Vaccine Corporation leading the collaborative discovery and development of a gram-negative vaccine for hospital acquired infections. Previously, she served as the first CEO of MassBiologics, the only non-profit FDA licensed vaccine and biologic manufacturer in the U.S. There, she recruited and led the scientific team that discovered multiple monoclonal antibodies targeted to infectious disease pathogens with three products reaching late stage development and two now commercially available. Before MassBiologics, Dr. Ambrosino was Associate Professor of Pediatrics at Dana-Farber Cancer Institute and Children’s Hospital. There, she was a National Institutes of Health-funded researcher and an internationally recognized expert in infectious diseases, vaccine immunology and vaccine clinical trial design.